Thomas Hagedorn - Electromed Independent Director

ELMD Stock  USD 16.41  0.15  0.92%   

Director

Mr. Thomas M. Hagedorn is Independent Director of Electromed Inc. He has also served for approximately fifteen years as president of entities in a of real estate and mortgage companies headquartered in Northern Virginia namely Premium Financial Services Premium Realty Ltd. and Premium Title Services a mortgage company real estate brokerage company and title insurance company respectively. As president of these entities Mr. Hagedorn manages all aspects of the companies activities including managing between one to five employees in each company maintaining records and funds with respect to escrow accounts of clients and coordinating responses in connection with regulatory audits of the escrow accounts managed by each company. Mr. Hagedorn has also been a founding investor for various startup ventures including Hansen Engine Corporation as well as several energy companies where new technology is a principal factor. Mr. Hagedorn is a former member of the Minnesota State Legislature and the U.S. Congress representing southern Minnesota. since 1997.
Age 67
Tenure 27 years
Address 500 Sixth Avenue NW, New Prague, MN, United States, 56071
Phone952 758 9299
Webhttps://smartvest.com

Electromed Management Efficiency

The company has return on total asset (ROA) of 0.0721 % which means that it generated a profit of $0.0721 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.104 %, meaning that it created $0.104 on every $100 dollars invested by stockholders. Electromed's management efficiency ratios could be used to measure how well Electromed manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to 0.08. In addition to that, Return On Assets is expected to decline to 0.04. At present, Electromed's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 45.6 M, whereas Non Current Assets Total are forecasted to decline to about 5.4 M.
The company currently holds 161 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Electromed has a current ratio of 4.73, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Electromed until it has trouble settling it off, either with new capital or with free cash flow. So, Electromed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Electromed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Electromed to invest in growth at high rates of return. When we think about Electromed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

William ZollarsCigna Corp
70
Peter NeupertLaboratory
65
Ian ClarkGuardant Health
57
John PartridgeCigna Corp
71
Stanley MeresmanGuardant Health
71
JeanLuc BelingardLaboratory
72
Donna ShalalaMednax Inc
75
Manuel KadreMednax Inc
54
Paul GabosMednax Inc
55
George KurianCigna Corp
54
Karey BarkerMednax Inc
52
James RogersCigna Corp
69
Waldemar CarloMednax Inc
67
Roman MartinezCigna Corp
71
Eric WisemanCigna Corp
65
Dipchand NisharGuardant Health
N/A
Sanders WilliamsLaboratory
69
Eric FossCigna Corp
62
Pascal GoldschmidtMednax Inc
65
Michael FernandezMednax Inc
66
Kerrii AndersonLaboratory
63
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of various ages in the United States and internationally. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota. Electromed operates under Medical Devices classification in the United States and is traded on AMEX Exchange. It employs 156 people. Electromed (ELMD) is traded on NYSE MKT Exchange in USA. It is located in 500 Sixth Avenue NW, New Prague, MN, United States, 56071 and employs 170 people. Electromed is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Electromed Leadership Team

Elected by the shareholders, the Electromed's board of directors comprises two types of representatives: Electromed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Electromed. The board's role is to monitor Electromed's management team and ensure that shareholders' interests are well served. Electromed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Electromed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amy Yanta, Quality Affairs
Diane Kaufman, Vice Resources
Thomas Hagedorn, Independent Director
Stan Erickson, Independent Director
William Eckles, Independent Director
Jeremy Brock, CFO
James Cunniff, Director President
Kathleen Skarvan, CEO and President and Director
George Winn, Vice Chairman of the Board
Brad Nagel, Chief Officer
William George, Secretary
Stephen Craney, Independent Chairman of the Board
Christopher Holland, Chief Officer
Lee Jones, Director
Bradley Nagel, Chief Officer

Electromed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Electromed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Electromed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Electromed's short interest history, or implied volatility extrapolated from Electromed options trading.

Pair Trading with Electromed

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Electromed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Electromed will appreciate offsetting losses from the drop in the long position's value.

Moving against Electromed Stock

  0.93SSY SunLink Health SystemsPairCorr
  0.86TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.74DYNT Dynatronics Financial Report 9th of May 2024 PairCorr
  0.68FIGS Figs Inc Financial Report 2nd of May 2024 PairCorr
  0.6MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
The ability to find closely correlated positions to Electromed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Electromed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Electromed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Electromed to buy it.
The correlation of Electromed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Electromed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Electromed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Electromed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Electromed is a strong investment it is important to analyze Electromed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Electromed's future performance. For an informed investment choice regarding Electromed Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Electromed. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Electromed Stock refer to our How to Trade Electromed Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Electromed Stock analysis

When running Electromed's price analysis, check to measure Electromed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Electromed is operating at the current time. Most of Electromed's value examination focuses on studying past and present price action to predict the probability of Electromed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Electromed's price. Additionally, you may evaluate how the addition of Electromed to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Electromed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Electromed. If investors know Electromed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Electromed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.727
Earnings Share
0.45
Revenue Per Share
6.072
Quarterly Revenue Growth
0.167
Return On Assets
0.0721
The market value of Electromed is measured differently than its book value, which is the value of Electromed that is recorded on the company's balance sheet. Investors also form their own opinion of Electromed's value that differs from its market value or its book value, called intrinsic value, which is Electromed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Electromed's market value can be influenced by many factors that don't directly affect Electromed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Electromed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Electromed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Electromed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.